Astellas seeks new Xtandi indication

Share this article:

Astellas and Medivation have made pursuit of a pre-chemo indication for Xtandi official: the two companies announced Tuesday that they have filed a supplemental New Drug Application with the FDA so the oral drug can be used by metastatic castration-resistant prostate cancer patients earlier in treatment.

The drug is currently approved for patients who have already received docetaxel. The companies released the Phase-III data that is the basis of Tuesday's submission in January. The data indicated that an earlier intervention bought patients progression-free time.

Phase-III results also indicated that prostate-specific antigen levels fell by at least 50% among 75% of the test group, and overall survival was 29% greater with pre-chemo use compared to placebo.

Adding a pre-chemo indication to a post-chemo drug is not a new strategy: Roche moved its breast cancer drug Perjeta into first-line treatment for early stage breast cancer patients in September.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions